Welcome to our dedicated page for Sage Therapeutics news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutics stock.
Sage Therapeutics, Inc. (SAGE) is a pioneering, neuroscience-focused biopharmaceutical company dedicated to developing medicines for life-threatening and rare central nervous system (CNS) disorders. Founded in 2010, Sage Therapeutics aims to improve the lives of patients suffering from various CNS diseases through breakthrough scientific research, robust clinical trials, and strong partnerships.
The company is primarily engaged in three key focus areas: depression, neurology, and neuropsychiatry. Sage's lead compound, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE), marking the first of many potential seizure medicines in its extensive pipeline. Another notable treatment, Zurzuvae, targets postpartum depression (PPD) in adults, while Zulresso is a CIV injection designed for individuals aged 15 and older dealing with PPD.
In addition to these approved treatments, the company’s pipeline features several promising compounds, including SAGE-324 and Dalzanemdor (SAGE-718), which are currently under various stages of development. Sage Therapeutics leverages two critical CNS receptor systems, GABA and NMDA, to develop its innovative treatments.
Sage’s commitment to compelling science and robust clinical foundations is fortified by its world-class team of founders, advisors, investors, scientists, and managers. The company prides itself on its collaborative efforts, fostering strategic partnerships to enhance its research and development capabilities. These efforts underscore Sage Therapeutics' mission to discover, develop, and deliver significant new medicines to address unmet medical needs in the CNS space.
Sage Therapeutics (NASDAQ: SAGE) has appointed Dr. Laura Gault as Chief Medical Officer. Dr. Gault brings over 15 years of experience in the pharmaceutical industry, having worked on development programs in neuropsychiatry and neuroinflammation. Her previous roles include Vice President at Alexion/AstraZeneca, where she contributed to significant drug developments. In her new position, Dr. Gault will focus on advancing Sage's product pipeline, driven by a commitment to improve brain health treatment options.
Sage Therapeutics (Nasdaq: SAGE) announced a live webcast on November 8, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results and recent business updates. The webcast will be accessible via the Investor page on Sage's website, with a replay available for 30 days post-event. Sage Therapeutics is focused on developing innovative solutions for brain health, aiming to deliver impactful medicines to enhance the quality of life.
Zuranolone 50 mg has shown improvement in depressive symptoms by Day 15 in the SKYLARK Study, with statistically significant results also at Days 3, 28, and 45. The study, presented at the ECNP Congress, highlighted the drug's rapid effect in women suffering from postpartum depression (PPD). Zuranolone was well-tolerated, with mild to moderate treatment-emergent adverse events. A New Drug Application (NDA) submission to the FDA for zuranolone is underway, aiming for completion in late 2022.
Sage Therapeutics and Biogen present new analyses on zuranolone, an investigational treatment for major depressive disorder (MDD) and postpartum depression (PPD), at Psych Congress in New Orleans from September 17 to 20, 2022. Key findings from the SHORELINE Study show a median of 135 days for repeat treatment in the 30 mg cohort. Results indicate sustained improvements in MDD symptoms and a favorable safety profile. Zuranolone is being evaluated under Fast Track and Breakthrough Therapy Designations by the FDA.
Sage Therapeutics, Inc. (Nasdaq: SAGE) has announced its presentation at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 3:40 p.m. ET in New York, NY. Investors can access a live webcast on the Company’s investor page, with a replay available two hours post-event and archived for 30 days. Sage Therapeutics focuses on pioneering solutions for brain health medicines, aiming to enhance the quality of life for individuals.
Sage Therapeutics reported Q2 2022 results, highlighting progress on the rolling NDA submission for zuranolone aimed at treating major depressive disorder (MDD) and postpartum depression (PPD). The company announced positive topline data from the Phase 3 SKYLARK Study for PPD and is enrolling multiple Phase 2 studies across neuropsychiatry and neurology. Despite a net loss of $126.3 million, the company expects its financial position to support operations into 2025. Sage anticipates cash and marketable securities of approximately $1.3 billion by year-end 2022.
Sage Therapeutics (Nasdaq: SAGE) announced its participation in two upcoming investor conferences in August 2022. The company will hold a fireside chat at the Wedbush PacGrow Healthcare Conference on
Sage Therapeutics, Inc. (Nasdaq: SAGE) announced a live webcast on August 2, 2022, at 8:00 a.m. ET to disclose its second quarter 2022 financial results and discuss recent business updates. Investors can access the webcast via the company's investor page. A replay will be available for 30 days post-event.
Sage Therapeutics, a biopharmaceutical company focused on brain health, announced its participation in two key investor conferences in June 2022. The Jefferies Healthcare Conference will feature a fireside chat on June 8 at 11:30am ET in New York, while the Goldman Sachs Annual Global Healthcare Conference is set for June 13 at 3:20pm PT (6:20pm ET) in Palos Verdes, CA. Live webcasts of both events can be accessed on Sage's investor website, with replays available afterward for 30 days.
Sage Therapeutics and Biogen announced successful results from the Phase 3 SKYLARK Study of zuranolone, an oral treatment for postpartum depression (PPD). The study achieved its primary endpoint, showing a statistically significant improvement in depressive symptoms at Day 15 with a change from baseline HAMD-17 total score of -15.6 for zuranolone compared to -11.6 for placebo (p=0.0007). Additionally, safety profiles were consistent with previous studies. Zuranolone aims to provide rapid relief for the one in eight women affected by PPD in the U.S.
FAQ
What is the current stock price of Sage Therapeutics (SAGE)?
What is the market cap of Sage Therapeutics (SAGE)?
What is Sage Therapeutics, Inc. focused on?
What are the key focus areas of Sage Therapeutics?
What are some of the main products of Sage Therapeutics?
What is SAGE-547?
What are the current projects in Sage Therapeutics' pipeline?
What receptor systems does Sage Therapeutics target?
When was Sage Therapeutics founded?
Who makes up the team at Sage Therapeutics?
What is the mission of Sage Therapeutics?
How does Sage Therapeutics enhance its research and development capabilities?
